CytoMed Therapeutics Limited

Equities

GDTC

SGXZ17669631

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:30:00 2024-06-14 EDT			5-day change	1st Jan Change
1.9 ^USD	-7.77%		-2.56%	-61.22%

05-24	CytoMed Therapeutics Limited Approves the Resignation of Wu Tao Thomas and Dr. Lucas Luk Tien Wee as Directors	CI
04-22	CytoMed Therapeutics Limited Reports Earnings Results for the Full Year Ended December 31, 2023	CI

CytoMed Therapeutics Limited Approves the Resignation of Wu Tao Thomas and Dr. Lucas Luk Tien Wee as Directors

May 24, 2024 at 11:12 am

CytoMed Therapeutics Limited held its 2024 annual meeting of shareholders, approved the resignation of Mr. Wu Tao Thomas and Dr. Lucas Luk Tien Wee as Directors. Both have given notice to the Company that they do not wish to stand for re-election as Directors.

Latest news about CytoMed Therapeutics Limited

CytoMed Therapeutics Limited Approves the Resignation of Wu Tao Thomas and Dr. Lucas Luk Tien Wee as Directors	05-24	CI
CytoMed Therapeutics Limited Reports Earnings Results for the Full Year Ended December 31, 2023	04-22	CI
Certain Ordinary Shares of CytoMed Therapeutics Limited are subject to a Lock-Up Agreement Ending on 14-APR-2024.	04-13	CI
CytoMed Therapeutics Limited to Launch Complimentary Cell Banking for Qualified Shareholders for Future Precision Therapies	03-18	CI
CytoMed Therapeutics Limited Announces Research Collaboration with Sengkang General Hospital Pte Ltd to Advance Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Diseases and Repair	03-04	CI
CytoMed Therapeutics Receives Patent in Malaysia for its Prospective Cancer Therapy	01-29	MT
CytoMed Therapeutics Limited Reports Earnings Results for the Half Year Ended June 30, 2023	11-17	CI
Top Premarket Decliners	23-10-18	MT
CytoMed Therapeutics' iPSC-Based Technology Obtains Patent From Chinese Patent Office to Treat Cancer	23-09-25	MT
CytoMed Therapeutics Limited Announces Entering into A Memorandum of Understanding with CNK Therapeutics Co., Ltd	23-08-29	CI
CytoMed Therapeutics Announces China Research Collaboration to Enhance Allogeneic CAR ?d T In Vivo Persistency	23-08-15	CI
Benchmark Starts CytoMed Therapeutics at Speculative Buy With $5 Price Target	23-07-21	MT
Top Premarket Decliners	23-07-12	MT
Top Premarket Gainers	23-07-11	MT
CytoMed Therapeutics Granted US Patent for its Licensed CAR-Gamma Delta T Cell Technology	23-07-06	MT
CytoMed Therapeutics Limited Announces Collaboration with MD Anderson Cancer Center to Advance Allogeneic Off-The-Shelf Gamma Delta T Cells in Oncology	23-05-09	CI
CytoMed Therapeutics Limited Reports Earnings Results for the Full Year Ended December 31, 2022	23-05-01	CI
CytoMed Closes $9.65 Million Initial Public Offering	23-04-18	MT
CytoMed Therapeutics Limited(NasdaqCM:GDTC) added to NASDAQ Composite Index	23-04-17	CI
CytoMed Therapeutic Shares Fall in Nasdaq Debut	23-04-14	MT
CytoMed Therapeutics Prices IPO at $4 per Share	23-04-14	MT
CytoMed Therapeutics Limited has completed an IPO in the amount of $9.649476 million.	23-04-13	CI
CytoMed Therapeutics Limited Reports Earnings Results for the Half Year Ended June 30, 2022	23-02-01	CI
CytoMed Therapeutics Limited has filed an IPO in the amount of $15 million.	22-11-18	CI

Chart CytoMed Therapeutics Limited

Duration

Period

More charts

Company Profile

CytoMed Therapeutics Limited is a pre-clinical biopharmaceutical company. The Company is focused on harnessing its licensed proprietary technologies to create cell-based immunotherapies for the treatment of human cancers. The development of its technologies has been inspired by the clinical success of existing CAR-T in treating hematological malignancies, as well as the clinical limitations and commercial challenges in extrapolating the CAR-T principle into treatment of solid tumors. It is developing three product candidates: CTM-N2D, iPSC-gdNKT and CTM-GDT. CTM-N2D is its lead product candidate, and it consists of expanded gamma delta T cells grafted with NKG2DL-targeting CAR to enhance anti-cancer cytotoxicity. Its second product candidate, iPSC-gdNKT, utilizes iPSC as a starting material to generate gdNKT, which is a synthetic hybrid of a gamma delta T cell and a NK cell. Its third product candidate, CTM-GDT, consists of expanded allogeneic gamma delta T cells.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Ratings for CytoMed Therapeutics Limited

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.9 USD

Average target price

5 USD

Spread / Average Target

+163.16%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
CYTOMED THERAPEUTICS LIMITED	-61.22%	21.93M
VERTEX PHARMACEUTICALS INCORPORATED	+18.15%	124B
REGENERON PHARMACEUTICALS, INC.	+18.02%	112B
ARGENX SE	+4.75%	22.94B
BIONTECH SE	-12.75%	22.22B
BEIGENE, LTD.	-9.86%	17.02B
GENMAB A/S	-15.45%	16.88B
WUXI APPTEC CO., LTD.	-39.94%	16.87B
NEUROCRINE BIOSCIENCES, INC.	+2.80%	13.63B
SAREPTA THERAPEUTICS, INC.	+27.39%	11.61B

Bio Therapeutic Drugs